<DOC>
	<DOCNO>NCT02106364</DOCNO>
	<brief_summary>The main purpose study compare efficacy safety new basal insulin , insulin peglispro , insulin glargine participant type 2 diabetes mellitus ( T2DM ) . Both drug give injection skin . Participants may continue take oral antihyperglycemic medication ( OAM ) study , prescribe personal physician . The study expect last 12 month participant .</brief_summary>
	<brief_title>A Study Insulin Peglispro ( LY2605541 ) Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Have T2DM ( per World Health Organization [ WHO ] Classification Diabetes ) treat insulin . Have diabetes least 1 year . Have receive least 2 oral antihyperglycemic medication ( OAMs ) least 3 month prior study . Have hemoglobin A1c ( HbA1c ) 7.0 % 11.0 % , inclusive , accord central lab screening . Have body mass index ( BMI ) ≤40 kilogram/square meter ( kg/m^2 ) . This inclusion criterion applies females childbearing potential ( surgically sterilize menarche 1year postmenopausal ) : breastfeeding , test negative serum pregnancy test , intend become pregnant study willing reliable method birth control . Insulin therapy : use insulin therapy ( outside pregnancy ) anytime past 2 year , except shortterm treatment acute condition , maximum 4 continuous week . Insulin use duration pregnancy consider exclusion criterion . Concomitant medication : rosiglitazone , pramlintide , glucagonlike peptide1 ( GLP1 ) receptor agonist ( example , exenatide , exenatide weekly , liraglutide ) use concurrently within 3 month prior screen . Local OAM restriction : participant OAMs , restriction cardiac , renal , hepatic disease maximum dose , local product regulation must apply . Weight loss medication : currently take , take within 3 month precede screening , prescription overthecounter medication promote weight loss . Severe hypoglycemia history : episode severe hypoglycemia within 6 month prior screen . Diabetic ketoacidosis ( DKA ) hyperglycemic hyperosmolar nonketotic coma ( HHNKC ) : 1 episode DKA hyperosmolar state/coma past 6 month . Cardiovascular : cardiac disease functional status New York Heart Association Class III IV ( per New York Heart Association [ NYHA ] Cardiac Disease Classification ) . Renal : history renal transplantation , currently receive renal dialysis serum creatinine ≥2 milligram/deciliter ( mg/dL ) ( 177 micromole/liter [ mol/L ] ) . Hepatic : obvious clinical sign symptom liver disease ( exclude nonalcoholic fatty liver disease [ NAFLD ] ) , acute chronic hepatitis , nonalcoholic steatohepatitis ( NASH ) , elevate liver enzyme measurement . Lipidlowering medication : Are use niacin preparation lipidlowering medication bile acid sequestrants within 90 day prior screen ; , Are use lipidlowering medication dose stable ≥90 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>